Plain-English translation of NCT07181161 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a first-in-human trial testing , a new medication designed to treat metastatic prostate cancer that has become resistant to standard hormone therapies. Researchers want to find the right dose and understand how safe this medication is, whether it works alone, and whether combining it with another drug called works better. The study will enroll about 177 participants across multiple medical centers.
Men with advanced prostate cancer often develop resistance to current hormone treatments, leaving them with limited options. This trial exists to see whether this new treatment approach can help patients whose cancer has stopped responding to standard care.
You likely qualify if…
You likely don't qualify if…
Participants will receive either the new medication alone or the new medication combined with another drug, depending on which study group they are assigned to. The trial involves multiple visits to the study center where researchers will monitor your health through blood tests, scans, and physical exams to track how the medication is working and watch for side effects. The study is designed in stages — early stages focus on finding the right and safest dose, while later stages evaluate how well the medication works.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States